Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - INNOVUS PHARMACEUTICALS, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): July 17,
2018
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
000-52991
|
90-0814124
|
(State or other
jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
8845 Rehco Road,
San Diego, CA
|
|
92122
|
(Address of
Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
|
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 2.02 – Results of Operations and Financial
Condition
On July
17, 2018, the Company issued a press release reporting our
preliminary expected financial results for the second quarter ended
June 30, 2018. The full text of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
Exhibit
No.
|
|
Description
|
|
Press
release issued July 17, 2018, reporting preliminary expected
financial results for the second quarter ended June 30,
2018
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
|||
|
|
||
Date: July 17, 2018
|
By:
|
/s/ RANDY BERHOLTZ
|
|
|
|
Randy Berholtz
Executive
Vice President, Corporate Development
and
General Counsel
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
|
Press
release issued July 17, 2018, reporting preliminary expected
financial results for the second quarter ended June 30,
2018
|